Reports
Sale
Global Peripheral Neuropathy Treatment Market Share, Trends: By Type: Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, Others; By Therapeutics Method; By End User; By Treatment Channel; Regional Analysis; Supplier Landscape; 2024-2032
Global Peripheral Neuropathy Treatment Market Outlook
The global peripheral neuropathy treatment market reached a value of about USD 764.27 million in 2023 and is expected to grow at a CAGR of 3.7% during the forecast period of 2024-2032. With the rising prevalence of chronic diseases, which increase the risk of peripheral neuropathy in chronic disease patients, the market is expected to reach USD 1,059.88 million by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Peripheral Neuropathy Treatment Market Insights
Peripheral neuropathy is a catch-all term for nerve diseases that affect a specific part of the nervous system. Peripheral neuropathy occurs when the nerves are damaged or destroyed and no longer functioning properly. This interferes with the normal functioning of the nerves. They may send pain signals when there is nothing causing pain, or they may not send a pain signal even if something is causing the pain. This could be because of systemic illness, infection, injury, an inherited disorder hormonal imbalance, certain medications, or vitamin deficiency.
Anyone, regardless of age, gender, race or ethnicity, personal circumstances, medical history, or other factors, can develop peripheral neuropathy. However, some people are predisposed to certain types of peripheral neuropathy. Some age-related diseases are also associated with peripheral neuropathy. As a result, the risk of developing peripheral neuropathy rises with age.
In the body, there are three types of nerves. Doctors will diagnose the type of peripheral neuropathy based on the group of nerves that it affects. The three groups are as follows:
- Motor: These nerves control muscle movements, such as walking, talking, or using the hands or arms.
- Sensory: These are in charge of sensory information, such as hot or cold, pain, or touch.
- Autonomic: These are in charge of non-visible body processes, such as breathing, heartbeat, and digestion.
Peripheral neuropathy is usually diagnosed using a combination of methods. Some of the examples are:
- Examinations of the blood (these can detect many problems, ranging from immune system problems to toxins and poisons, especially metals like mercury or lead)
- Electromyogram
- Ultrasound of the nerves
- Biopsy of a nerve
- Genetic analysis
- Magnetic resonance imaging (MRI)
According to the peripheral neuropathy treatment market research report, the market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Type
- Diabetic Peripheral Neuropathy
- Chemotherapy-Induced Peripheral Neuropathy
- Idiopathic Peripheral Neuropathy
- HIV/AIDS Associated Peripheral Neuropathy
Market Breakup by Treatment Method
- Pharmacological Therapies
- Pain Relievers
- Anti-Seizure Medications
- Anti-Depressants
- Non-Pharmacological Therapies
- Transcutaneous Electrical Nerve Stimulation
- Plasma Exchange
- Others
- Others
Peripheral Neuropathy Treatment Market Breakup by End User
- Hospitals and Clinics
- Retail Pharmacy
- Online Pharmacy
Market Breakup by Treatment Channel
- Public
- Private
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Peripheral Neuropathy Epidemiology
Peripheral neuropathy is common because it refers to so many different conditions. Peripheral neuropathy affects approximately 2.4% of the world's population. That percentage rises to between 5% and 7% among people aged 45 and above. Peripheral neuropathy affects approximately 2.4% of the population. In older populations, the prevalence rises to 8%.
Peripheral neuropathy can be a symptom of a variety of pathologies that require further investigation and/or treatment. Furthermore, peripheral neuropathies must be treated before they cause complications, such as falls that result in hip fractures or pedal infections that necessitate amputation.
Global Peripheral Neuropathy Therapeutic Landscape
Peripheral neuropathy treatment can vary greatly depending on the cause. In general, the following methods of treatment are more commonly used for peripheral neuropathy:
Medications: Many medications are available to treat peripheral nervous system issues. Injections, pills taken by mouth, patches that stick to the skin, slow-release medication, and other options are available.
Surgery: Surgery can help reconnect severed nerves and alleviate pain caused by trapped nerves. It can also cut or remove damaged or malfunctioning nerves, preventing signals from reaching the brain and vice versa.
Physical Therapy: This can assist in recovering from injuries or medical procedures, as well as improving pain symptoms. It can also help adapt to changes in the nervous system, such as improving balance and preventing falls.
Wearable Devices and Equipment: These include medical devices such as braces, canes, and walkers, and prescribed footwear. These do not treat peripheral neuropathy directly, but they can help prevent complications. One example is special footwear for people with Type 2 diabetes who have peripheral neuropathy.
If standard medications do not relieve the pain from peripheral neuropathy or nerve injury, pain specialists may occasionally recommend alternative treatments, such as acupuncture, transcutaneous electrical nerve stimulation, injections, or surgery to implant a spinal cord stimulator.
Global Peripheral Neuropathy Market Drivers and Restraint
The rising prevalence of chronic diseases such as diabetes, cancer, and hypothyroidism, which increase the risk of peripheral neuropathy in chronic disease patients, and rising cancer prevalence is expected to drive the global peripheral neuropathy treatment market growth over the forecast period.
High product costs and the availability of alternative treatments, as well as stringent regulatory compliance and device recalls, are major factors impeding growth in the global market. The rising cost of drugs used in the treatment of peripheral neuropathy and the increasing availability of alternative therapies for the treatment of peripheral neuropathy, are some of the factors constraining the market growth.
Competitive Landscape
The report gives an in-depth analysis of the key players involved in the global peripheral neuropathy treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Abbott Laboratories
- Bristol Myers Squibb Co
- Novartis AG
- Eli Lilly and Company
- Pfizer Inc.
- GlaxoSmithKline Plc
- Merck and Co. Inc.
- F. Hoffmann-La Roche Ltd
- Cipla Ltd.
- Lupin Ltd
- Dr. Reddy’s Laboratories
- RxFunction, Inc.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Therapeutics Method |
|
| Breakup by End User |
|
| Breakup by Treatment Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.1.1 Research Objectives
1.1.2 Key Findings of the Report
1.2 Limitations of the Study and Scope for Future Research
2 Research Methodology
3 Executive Summary
4 Global Peripheral Neuropathy Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Global Peripheral Neuropathy Treatment Market
6.1 Global Peripheral Neuropathy Treatment Market Overview
6.2 Global Peripheral Neuropathy Treatment Market Analysis
6.2.1 Market Overview
6.2.1.1 Global Peripheral Neuropathy Treatment Market Historical Value (2017-2023)
6.2.1.2 Global Peripheral Neuropathy Treatment Market Forecast Value (2024-2032)
6.3 Global Peripheral Neuropathy Treatment Market by Type
6.3.1 Market Overview
6.3.1.1 Diabetic Peripheral Neuropathy
6.3.1.2 Chemotherapy-Induced Peripheral Neuropathy
6.3.1.3 Idiopathic Peripheral Neuropathy
6.3.1.4 HIV/AIDS Associated Peripheral Neuropathy
6.4 Global Peripheral Neuropathy Treatment Market by Therapeutics Method
6.4.1 Market Overview
6.4.1.1 Pharmacological Therapies
6.4.1.1.1 Pain Relievers
6.4.1.1.2 Anti-Seizure Medications
6.4.1.1.3 Anti-Depressants
6.4.1.2 Non-Pharmacological Therapies
6.4.1.2.1 Transcutaneous Electrical Nerve Stimulation
6.4.1.2.2 Plasma Exchange
6.4.1.2.3 Others
6.4.1.3 Others
6.5 Global Peripheral Neuropathy Treatment Market by End User
6.5.1 Market Overview
6.5.1.1 Hospitals And Clinics
6.5.1.2 Retail Pharmacy
6.5.1.3 Online Pharmacy
6.6 Global Peripheral Neuropathy Treatment Market by Treatment Channel
6.6.1 Public
6.6.2 Private
6.7 Global Peripheral Neuropathy Treatment Market by Region
6.7.1 Market Overview
6.7.1.1 North America
6.7.1.1.1 Historical Trend (2017-2023)
6.7.1.1.2 Forecast Trend (2024-2032)
6.7.1.2 Europe
6.7.1.2.1 Historical Trend (2017-2023)
6.7.1.2.2 Forecast Trend (2024-2032)
6.7.1.3 Asia Pacific
6.7.1.3.1 Historical Trend (2017-2023)
6.7.1.3.2 Forecast Trend (2024-2032)
6.7.1.4 Latin America
6.7.1.4.1 Historical Trend (2017-2023)
6.7.1.4.2 Forecast Trend (2024-2032)
6.7.1.5 Middle East and Africa
6.7.1.5.1 Historical Trend (2017-2023)
6.7.1.5.2 Forecast Trend (2024-2032)
7 North America Peripheral Neuropathy Treatment by Treatment Market
7.1 United States of America
7.1.1 Historical Trend (2017-2023)
7.1.2 Forecast Trend (2024-2032)
7.2 Canada
7.2.1 Historical Trend (2017-2023)
7.2.2 Forecast Trend (2024-2032)
8 Europe Peripheral Neuropathy Treatment by Treatment Market
8.1 United Kingdom
8.1.1 Historical Trend (2017-2023)
8.1.2 Forecast Trend (2024-2032)
8.2 Germany
8.2.1 Historical Trend (2017-2023)
8.2.2 Forecast Trend (2024-2032)
8.3 France
8.3.1 Historical Trend (2017-2023)
8.3.2 Forecast Trend (2024-2032)
8.4 Italy
8.4.1 Historical Trend (2017-2023)
8.4.2 Forecast Trend (2024-2032)
9 Asia Pacific Peripheral Neuropathy Treatment by Treatment Market
9.1 China
9.1.1 Historical Trend (2017-2023)
9.1.2 Forecast Trend (2024-2032)
9.2 Japan
9.2.1 Historical Trend (2017-2023)
9.2.2 Forecast Trend (2024-2032)
9.3 India
9.3.1 Historical Trend (2017-2023)
9.3.2 Forecast Trend (2024-2032)
9.4 ASEAN
9.4.1 Historical Trend (2017-2023)
9.4.2 Forecast Trend (2024-2032)
9.5 Australia
9.5.1 Historical Trend (2017-2023)
9.5.2 Forecast Trend (2024-2032)
10 Latin America Peripheral Neuropathy Treatment by Treatment Market
10.1 Brazil
10.1.1 Historical Trend (2017-2023)
10.1.2 Forecast Trend (2024-2032)
10.2 Argentina
10.2.1 Historical Trend (2017-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 Mexico
10.3.1 Historical Trend (2017-2023)
10.3.2 Forecast Trend (2024-2032)
11 Middle East and Africa Peripheral Neuropathy Treatment by Treatment Market
11.1 Saudi Arabia
11.1.1 Historical Trend (2017-2023)
11.1.2 Forecast Trend (2024-2032)
11.2 United Arab Emirates
11.2.1 Historical Trend (2017-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 Nigeria
11.3.1 Historical Trend (2017-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 South Africa
11.4.1 Historical Trend (2017-2023)
11.4.2 Forecast Trend (2024-2032)
12 Current Scenario Evaluation and Regulatory Framework
12.1 Emerging Therapies and Clinical Trials Synopsis
12.2 Patent Landscape
12.2.1 Patent Overview
12.2.1.1 Patent Status and Expiry
12.2.1.2 Timelines from Drug Development to Commercial Launch
12.2.1.3 New Drug Application
12.2.1.3.1 Documentation and Approval Process
12.3 Cost of Treatment
12.4 Regulatory Framework
12.4.1 Regulatory Overview
12.4.1.1 US FDA
12.4.1.2 EU EMA
12.4.1.3 INDIA CDSCO
12.4.1.4 JAPAN PMDA
12.4.1.5 Others
13 Challenges and Unmet Needs
13.1 Treatment Pathway Challenges
13.2 Compliance and Drop-Out Analysis
13.3 Awareness and Prevention Gaps
14 Global Peripheral Neuropathy Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Abbott Laboratories
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Bristol Myers Squibb Co
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Novartis AG
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Eli Lilly and Company
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Pfizer Inc.
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 GlaxoSmithKline Plc
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Merck and Co. Inc.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 F. Hoffmann-La Roche Ltd
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Cipla Ltd.
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Lupin Ltd
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Dr. Reddy’s Laboratories
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
15.12 RxFunction, Inc.
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.12.5 Certifications
16 Recommendations and Discussion
17 Global Peripheral Neuropathy Treatment Drugs Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
18 Payment Methods (Additional Insight)
18.1 Government Funded
18.2 Private Insurance
18.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of USD 764.27 million in 2023.
The market is likely to grow at a CAGR of 3.7% during the forecast period of 2024-2032.
The market is expected to reach a value of USD 1,059.88 million by 2032.
The rising prevalence of chronic diseases, such as diabetes, cancer, and hypothyroidism, increases the risk of peripheral neuropathy in chronic disease patients.
The major regional markets include North America, Europe, Latin America, Middle East and Africa, and Asia Pacific.
The major types include diabetic, chemotherapy-induced, idiopathic, and HIV/AIDS associated peripheral neuropathy.
The key players in the market include Abbott Laboratories, Bristol Myers Squibb Co, Novartis AG, Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline Plc, Merck and Co. Inc., F. Hoffmann-La Roche Ltd, Cipla Ltd., Lupin Ltd, Dr. Reddy’s Laboratories, and RxFunction, Inc., among others.
High product costs, availability of alternative treatments, and stringent regulatory compliance and device recalls, are major factors impeding the market growth.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER